Session Synopsis: This panel promises an exciting discussion around the interplay between universities and entrepreneurship, the creation of intellectual property and building biotech. Different leaders across academia, venture capital, and companies will join this discussion of how to connect university activities and researchers with the emerging biotech sector for successful business development that can catapult the Research Triangle beyond Silicon Valley.
Session Chair Profile
M.D., Chancellor Emeritus, Duke University
Ralph Snyderman, MD is Chancellor Emeritus, Duke University and James B. Duke Professor of Medicine in the Duke University School of Medicine. He served as Chancellor for Health Affairs and Dean of the School of Medicine at Duke University from 1989 to July 2004 and led the transition of this excellent medical center into an internationally recognized leader of academic medicine. He oversaw the development of the Duke University Health System, one of the most successful integrated academic health systems in the country, and served as its first President and Chief Executive Officer. Dr. Snyderman has played a leading role in the conception and development of Personalized Health Care, an evolving model of national health care delivery. He was amongst the first to envision and articulate the need to move the current focus of health care from the treatment of disease-events to personalized, predictive, preventive, and participatory care that is focused on the patient. Dr. Snyderman is the recipient of numerous awards recognizing his contributions to research and to developing more rational models of health care. In 2012, he received the David E. Rogers Award from the Association of American Medical Colleges who referred to Snyderman as “the father of personalized medicine.”
Advancing Precision Medicine into Practice: Clinical Models
Precision medicine technologies are rapidly providing new capabilities to improve the delivery of health care but to do so they need to be efficiently adopted into practice. Current clinical approaches and workflows are not well designed to adopt precision technologies and clinical redesign is needed to advance the adoption of precision medicine into practice. Suggestions for such clinical approaches and work flows will be presented.
M.D., MPH, Dean, UNC School of Medicine; Vice Chancellor for Medical Affairs, University of North Carolina at Chapel Hill; and CEO, UNC Health Care System.
Dr. Roper is professor of health policy and management in the School of Public Health, and is professor of pediatrics and of social medicine in the School of Medicine at UNC. From 1997 until 2004, he was dean of the School of Public Health at UNC. Before joining UNC in 1997, Dr. Roper was senior vice president of Prudential HealthCare. He joined Prudential in 1993 as president of the Prudential Center for Health Care Research. Before coming to Prudential, Dr. Roper was director of the Centers for Disease Control and Prevention (CDC), served on the senior White House staff, and was administrator of the Health Care Financing Administration (responsible for Medicare and Medicaid). Earlier, he was a White House Fellow. He received his MD from the University of Alabama School of Medicine, and his MPH from the University of Alabama at Birmingham School of Public Health. He completed his residency in pediatrics at the University of Colorado Medical Center. Dr. Roper is a member of the National Academy of Medicine (formerly the Institute of Medicine). He is a member of the board of directors of DaVita, Inc., and a member of the board of directors ofExpress Scripts Holding Company. He lives with his wife Dr. Maryann Roper, a pediatric oncologist, and their son, Will, in Chapel Hill, North Carolina.
President, US Pharmaceuticals, GlaxoSmithKline; MBA, Keenan Flagler School of Business, University of North Carolina
Jack Bailey oversees GSK’s pharmaceuticals and vaccines businesses in the US and Puerto Rico. In this role, Jack draws upon 25 years of industry experience and a successful track record of leading organizations through change, delivering strong business performance and maintaining a focus on patient access and affordability. Jack joined GSK in 2009 as senior vice president leading groups responsible for payers, public policy, and government affairs. Prior to joining GSK, Jack had a successful 18-year career with Eli Lilly, where he served in a variety of commercial leadership roles including senior vice president of the account-based markets division, general manager for South Africa, and area director for the sub-Saharan region. Jack lives in North Carolina with his wife and two children. He is actively involved with the NC Biotechnology Center, the NC Healthcare Quality Alliance, the NC Chamber of Commerce and the Health Policy and Management Executive Council at the Harvard T.H. Chan School of Public Health.
MPH, MBA, President and CEO, North Carolina Biotechnology Center
Doug Edgeton has extensive executive-level experience in health care, research park development, and business administration. Edgeton has managed both talent and facilities to create an ecosystem for organizational growth. He translates this to his leadership role at NCBiotech, where he targets state investment and staff expertise to help North Carolina’s life science companies grow, create jobs, and bring life-changing technologies to market. He joined NCBiotech in 2012 as senior vice president for financial planning and development, and conducted a top-to-bottom examination of programs, staffing and finances. He then led the development and implementation of a new strategy when he became President and CEO in 2014. Prior to NCBiotech, Edgeton held senior roles with the medical school and health system at Wake Forest University, laying the groundwork for the Piedmont Triad Research Park. Prior to that he served as the Associate Dean at the University of Alabama School of Medicine.
Ph.D., Chancellor, North Carolina State University
Dr. Randy Woodson, the 14th chancellor of North Carolina State University, is a nationally recognized scholar and academic leader who oversees the largest university in North Carolina, with more than 34,000 students and a $1.4 billion budget. Under his leadership, NC State expanded its reputation as a pre-eminent research institution. Woodson’s strategic plan aligned the university for greater effectiveness, efficiency and — most importantly — student success. Chancellor Woodson has extensive experience as a member of university faculty and administration, with a reputation for consensus building throughout his 30-year career in higher education. He came to NC State from Purdue University, where he most recently served as executive vice president for academic affairs. Woodson is an internationally renowned plant molecular biologist specializing in reproductive processes in agricultural crops. He earned his undergraduate degree in horticulture from the University of Arkansas and his M.S. and Ph.D. degrees in plant physiology from Cornell University.